小剂量左甲状腺素治疗糖尿病合并甲状腺功能亢进患者的效果

doi:10.3760/cma.j.issn.1007-1245.2024.21.025

摘要/Abstract

摘要：

目的　观察小剂量左甲状腺素治疗糖尿病合并甲状腺功能亢进患者的效果。方法　选取杨凌示范区医院2023年1月至2024年1月收治的136例糖尿病合并甲状腺功能亢进患者进行随机对照试验。采用随机数字表法将其分为常规组和小剂量组，各68例。常规组男32例，女36例，年龄（54.85±9.63）岁；糖尿病病程（7.12±2.05）年，甲状腺功能亢进病程（2.56±0.89）年。小剂量组男37例，女31例，年龄（55.12±10.14）岁，糖尿病病程（7.08±2.12）年，甲状腺功能亢进病程（2.51±0.92）年。常规组采用甲巯咪唑联合达格列净治疗；小剂量组在常规组基础上联合小剂量左甲状腺素治疗；两组均治疗6个月。两组血糖指标、胰岛素功能指标、肠道菌群、甲状腺激素水平比较采用t检验，两组临床疗效和安全性比较采用χ²检验。结果　治疗后，两组空腹血糖、胰岛素抵抗指数、餐后2 h血糖、糖化血红蛋白均低于治疗前，且小剂量组空腹血糖、胰岛素抵抗指数、餐后2 h血糖、糖化血红蛋白均低于常规组［（6.34±0.78）mmol/L比（7.28±1.04）mmol/L、（2.63±0.34）比（3.41±0.37）、（8.27±1.76）mmol/L比（9.54±2.04）mmol/L、（6.74±1.12）%比（8.31±1.65）%；t=5.963、12.800、3.887、6.492，均P<0.05］；两组胰岛β细胞指数均高于治疗前，且小剂量组胰岛β细胞指数高于常规组［（65.75±10.15）比（54.86±8.09）；t=6.919，P<0.05］。治疗后，两组肠杆菌、肠球菌、双歧杆菌、乳酸杆菌数量差异均无统计学意义（均P>0.05）。治疗后，两组游离三碘甲状腺原氨酸、游离甲状腺素水平均低于治疗前，且小剂量组水平均低于常规组［（4.41±1.33）ng/L比（6.89±2.12）ng/L、（10.25±3.77）ng/L比（14.56±5.14）ng/L；t=8.172、5.576，均P<0.05］；两组促甲状腺激素水平均高于治疗前，且小剂量组高于常规组［（3.32±0.72）ng/L比（2.74±0.58）ng/L；t=5.173，P<0.05］。小剂量组总有效率高于常规组［92.65%（63/68）比79.41%（54/68）；P<0.05］。小剂量组肝损伤、继发性甲状腺功能减退、低血糖、胃肠道不适等总不良反应发生率为11.76%（8/68），常规组为8.82%（6/68），差异无统计学意义（P>0.05）。结论　小剂量左甲状腺素可调节糖尿病合并甲状腺功能亢进患者甲状腺激素表达，有利于控制血糖和改善胰岛素功能。

关键词:

糖尿病, 甲状腺功能亢进, 小剂量, 左甲状腺素, 甲状腺激素, 胰岛素功能

Abstract:

Objective　To observe the effect of low-dose levothyroxine in the treatment of patients with diabetes mellitus and hyperthyroidism. Methods　A total of 136 patients with diabetes mellitus and hyperthyroidism treated at Yangling Demonstration District Hospital from January 2023 to January 2024 were selected for the randomized controlled trial, and were divided into a conventional group and a small-dose group by the random number table method. There were 32 males and 36 females in the conventional group; they were (54.85±9.63) years old; their diabetic course was (7.12±2.05) years; their hyperthyroidism course was (2.56±0.89) years. There were 37 males and 31 females in the small-dose group; they were (55.12±10.14) years old; their diabetic course was (7.08±2.12) years; their hyperthyroidism course was (2.51±0.92) years. The conventional group were treated with methimazole and dagliflozin; in addition, the small-dose group were treated with small-dose levothyroxine. Both groups were treated for 6 months. The blood glucose indicators, insulin function indicators, intestinal flora, and thyroid hormone levels were compared between the two groups by t test. The clinical efficacies and safety of the two groups were compared by χ² test. Results　After the treatment, the fasting blood glucose, insulin resistance index, postprandial 2 h blood glucose, and glycated hemoglobin were lower than those before the treatment in both groups, and those in the small-dose group were lower than those in the conventional group [(6.34±0.78) mmol/L vs. (7.28±1.04) mmol/L, (2.63±0.34) vs. (3.41±0.37), (8.27±1.76) mmol/L vs. (9.54±2.04) mmol/L, and (6.74±1.12)% vs. (8.31±1.65)%; t=5.963, 12.800, 3.887, and 6.492; all P<0.05]; the islet β-cell indices of the two groups were higher than those before the treatment, and the islet β-cell index in the small-dose group was higher than that in the conventional group [(65.75±10.15) vs. (54.86±8.09); t=6.919; P<0.05]. After the treatment, there were no statistical differences in the numbers of Enterobacteriaceae, Enterococci, Bifidobacteria, and Lactobacillus between the two groups (all P>0.05). After the treatment, the levels of free triiodothyronine and free thyroxine were lower than those before the treatment in both groups, and the levels in the small-dose group were lower than those in the conventional group [(4.41±1.33) ng/L vs. (6.89±2.12) ng/L and (10.25±3.77) ng/L vs. (14.56±5.14) ng/L; t=8.172 and 5.576; both P<0.05]; the levels of thyrotropin in both groups were higher than those before the treatment, and the level in the small-dose group was higher than that in the conventional group [(3.32±0.72) ng/L vs. (2.74±0.58) ng/L; t=5.173; P<0.05]. The total effective rate in the small-dose group was higher than that in the conventional group [92.65% (63/68) vs. 79.41% (54/68); P<0.05]. The total incidence of adverse reactions, such as liver injury, secondary hypothyroidism, hypoglycaemia, and gastrointestinal discomfort, in the small-dose group was 11.76% (8/68), and that in the conventional group 8.82% (6/68), with no statistical difference (P>0.05). Conclusion　Small-dose levothyroxine can modulate thyroid hormone expression in patients with diabetes mellitus and hyperthyroidism, facilitate glycaemic control, and improve their insulin function.

Key words:

Diabetes mellitus, Hyperthyroidism, Small-dose, Levothyroxine, Thyroid hormones, Insulin function

高萌胡文华李伟.

小剂量左甲状腺素治疗糖尿病合并甲状腺功能亢进患者的效果 [J]. 国际医药卫生导报, 2024, 30(21): 3651-3656.

Gao Meng, Hu Wenhua, Li Wei.

Effectiveness of low-dose levothyroxine in treatment of patients with diabetes mellitus and hyperthyroidism [J]. International Medicine and Health Guidance News, 2024, 30(21): 3651-3656.

参考文献

[1] Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis[J]. Lancet Diabetes Endocrinol,2023,11(4):282-298. DOI: 10.1016/S2213-8587(23)00005-0.
[2] Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer[J]. Diabetes Care, 2023, 46(2): 384-390. DOI: 10.2337/dc22-1148.
[3] Kim SY. Diabetes and hyperthyroidism: is there a causal link? [J]. Endocrinol Metab (Seoul), 2021, 36(6): 1175-1177. DOI: 10.3803/EnM.2021.602.
[4] 宋洁. 左甲状腺素钠联合甲巯咪唑治疗年龄>60岁弥漫性毒性甲状腺肿患者的疗效评价 [J]. 中国药物与临床, 2021 ,21(19): 3252-3254. DOI:10.11655/zgywylc2021.19.012.
[5] 刘帆,刘彤,孟银苹. 小剂量左甲状腺素三联治疗糖尿病合并甲状腺功能亢进的疗效[J]. 西北药学杂志,2023,38(2):147-150. DOI: 10.3969/j.issn.1004-2407.2023.02.025.
[6] 欧阳建,刘莲,陈建斌,等. 甲巯咪唑联合左甲状腺素治疗毒性弥漫性甲状腺肿的临床效果分析[J]. 中国基层医药, 2020, 27(19): 2315-2318. DOI: 10.3760/cma.j.issn.1008-6706.2020.19.003.
[7] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI:10.3760/cma.j.cn115791-20210221-00095.
[8] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 甲状腺功能亢进症基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(12):1118-1128. DOI: 10.3760/cma.j.issn.1671-7368.2019.12.002.
[9] Roa Dueñas OH, Van der Burgh AC, Ittermann T, et al. Thyroid function and the risk of prediabetes and type 2 diabetes [J]. J Clin Endocrinol Metab, 2022, 107(6): 1789-1798. DOI: 10.1210/clinem/dgac006.
[10] Popoviciu MS, Paduraru L, Nutas RM, et al. Diabetes mellitus secondary to endocrine diseases: an update of diagnostic and treatment particularities[J]. Int J Mol Sci, 2023, 24(16): 12676. DOI: 10.3390/ijms241612676.
[11] Mohammed Hussein SM, AbdElmageed RM. The relationship between type 2 diabetes mellitus and related thyroid diseases[J]. Cureus, 2021, 13(12): e20697. DOI: 10.7759/cureus.20697.
[12] Gupta R, Kalra P, Ramamurthy LB, et al. Thyroid eye disease and its association with diabetes mellitus: a major review[J]. Ophthalmic Plast Reconstr Surg, 2023, 39(6S): S51-S64. DOI: 10.1097/IOP.0000000000002449.
[13] 刘帆,刘彤,孟银苹. 小剂量左甲状腺素三联治疗糖尿病合并甲状腺功能亢进的疗效[J]. 西北药学杂志,2023,38(2):147-150. DOI: 10.3969/j.issn.1004-2407.2023.02.025.
[14] 王脉桃. 二甲双胍与阿卡波糖对2型糖尿病合并甲亢患者的疗效比较[J]. 内蒙古医科大学学报, 2020, 42(3): 318-321. DOI: 10.3969/j.issn.1004-2407.2023.02.025.
[15] Higa S, Maesato A, Ishigaki S, et al. Diabetes and endocrine disorders (hyperthyroidism/hypothyroidism) as risk factors for atrial fibrillation[J]. Card Electrophysiol Clin, 2021, 13(1): 63-75. DOI: 10.1016/j.ccep. 2020.11.005.
[16] 张学敏,张高潮,宋晏,等. 左甲状腺素联合131I治疗甲状腺功能亢进症的临床研究[J]. 川北医学院学报,2023,38(1):28-31. DOI: 10.3969/j.issn.1005-3697.2023.01.007.
[17] 刘丹,郝伟迤,苏强,等. 不同剂量左甲状腺素联合硒酵母片对原发性甲状腺功能减退患者的临床疗效、甲状腺功能及血脂代谢影响[J]. 解放军医药杂志, 2021, 33(6): 67-70. DOI: 10.3969/j.issn.2095-140X.2021.06.014.
[18] 王伟伟,胡文华,许莹. 左甲状腺素钠在老年甲状腺功能减退综合征治疗中的应用[J]. 海南医学,2021,32(13):1662-1664. DOI:10.3969/j.issn.1003-6350.2021.13.009.
[19] 胡绍波, 梁丽丽, 李珊, 等. 甲巯咪唑联合双膦酸盐对甲亢性骨质疏松大鼠骨密度的影响[J]. 热带医学杂志, 2023, 23(4): 480-483, 502. DOI: 10.3969/j.issn.1672-3619. 2023.04.010.
[20] 周易, 陈影, 陈尔真. 甲状腺激素对脓毒症脏器功能维护作用的研究进展[J]. 内科理论与实践, 2022, 17(5): 408-412. DOI: 10.16138/j.1673-6087.2022.05.013.
[21] Abbey EJ, McGready J, Sokoll LJ, et al. Free thyroxine distinguishes subclinical hypothyroidism from other aging-related changes in those with isolated elevated thyrotropin[J]. Front Endocrinol (Lausanne), 2022, 13: 858332. DOI: 10.3389/fendo.2022.858332.
[22] Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial[J]. BMC Endocr Disord, 2021, 21(1): 16. DOI: 10.1186/s12902-020-00670-w.
[23] 马兴坡, 牛敏, 申金付, 等. 甲亢患者骨代谢指标与甲状腺激素的相关性及对甲亢性疏松的预测价值[J]. 河北医学, 2021, 27(7): 1085-1090. DOI: 10.3969/j.issn.1006-6233.2021.07.006.
[24] 章华,金婷婷,濮菲菲. 彩色多普勒超声联合甲状腺激素在妊娠期甲亢伴Graves病的应用价值[J]. 医学影像学杂志,2023,33(3):522-525.(无DOI)
[25] Li C, Wang KL, Hu JH, et al. Clinical manifestations and early effectiveness of methimazole in patients with Graves' hyperthyroidism-related severe hepatic dysfunction[J]. Scand J Gastroenterol, 2023, 58(12): 1514-1522. DOI: 10.1080/00365521.2023.2244107.